PEGYLATED INTERSFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV

聚乙二醇化干扰素/利巴韦林治疗丙型肝炎儿童

• 批准号: 7380746
• 负责人: MAUREEN M JONAS
• 金额: $ 1.26万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380746
• 关键词: PEGYLATED; INTERSFERON; RIBAVIRIN; CHILDREN; HCV

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The over-all goals of this application are: 1) To assess the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children. 2) TO determine whether PEG-2a in combination with RV or PEG-2a alone will result in a higher sustained virologic response rate in children with CHC. 3) To examine the effects of PEG-2a (wuith or without concomitant RV) treatment on body mass index, body composition, and linear growth in children infected with hepatitis C. 4) To characterize short- and long-term outcomes, including health-related QOL, gognitive and developmental and psychological functioning and behavior in children treated with PEG-2a (withor without concomitant RV).

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项应用的总体目标是：1)评估聚乙二醇化干扰素α-2a(PEG-2a)与利巴韦林(RV)和单独使用聚乙二醇单用干扰素α-2a治疗儿童慢性丙型肝炎病毒(CHC)感染的安全性和有效性。2)确定聚乙二醇2a联合RV或单用聚乙二醇2a对慢性丙型肝炎患儿的持续病毒学应答率是否较高。3)检测聚乙二醇2a(有或无伴随轮状病毒)治疗对感染丙型肝炎的儿童的体重指数、身体成分和线性生长的影响。4)表征接受聚乙二醇2a(有或不伴随轮状病毒)治疗的儿童的短期和长期结果，包括与健康相关的生活质量、智力和发育、心理功能和行为。